Personal profile
Education/Academic qualification
Post Doctoral Fellow, University Of Kentucky
2021
Residency, University Of Missouri- Kansas City
2018
Doctor of Medicine, Hashemite University
2012
Expertise related to UN Sustainable Development Goals
In 2015, UN member states agreed to 17 global Sustainable Development Goals (SDGs) to end poverty, protect the planet and ensure prosperity for all. This person’s work contributes towards the following SDG(s):
-
SDG 3 Good Health and Well-being
Fingerprint
- 1 Similar Profiles
Collaborations and top research areas from the last five years
-
IOV EAP: Expanded Access Program of AMTAGVI that is Out of Specification for Commercial Release
Arays, R. (PI) & Qasrawi, A. (CoI)
Iovance Biotherapeutics Incorporated
11/23/25 → 11/23/27
Project: Research project
-
25-LEUK-29-KO(KO-MEN-017): Phase 3 Randomized, Double-Blind, Placebo-controlled Studies Assessing Ziftomenib in Combination with Either Standard of Care Nonintensive (Venetoclax+Azacitidine) or Intensive (7+3) Therapy in Patients with Untreated NPM1 Mutat
Qasrawi, A. (PI)
11/13/25 → 11/13/27
Project: Research project
-
25-LEUK-28-JRD (75276617AML3001): A Phase 3 Randomized, Double-blind, Placebo-controlled, Study of Bleximenib, Venetoclax and Azacitidine for the Treatment of Participants with Newly Diagnosed Acute Myeloid Leukemia Harboring KMT2ARearrangements or NPM1Mu
Qasrawi, A. (PI)
Janssen Research and Development LLC
8/21/25 → 8/21/27
Project: Research project
-
24-LEUK-27-DS(AC220-168): Phase 3, Double-Blind, Randomized, Placebo-Controlled Trial Of Quizartinib Administered in Combination With Induction and Consolidation Chemotherapy and Administered as Maintenance Therapy in Adult Patients With Newly Diagnosed F
Qasrawi, A. (PI)
4/22/25 → 4/22/27
Project: Research project
-
Rapcabtagene: A Phase 2, Adaptive, Randomized, Open-Label, Assessor-Blinded Active-Controlled Study to Evaluate the Efficacy and Safety of Rapcabtagene Autoleucel vs. SOC in Patients Suffering from Systemic Lupus Erythematosus (SLE) with Active, Refractor
Piranavan, P. (PI), Ahmed, S. (CoI), Alkilany, R. (CoI) & Qasrawi, A. (CoI)
11/8/24 → 12/21/30
Project: Research project
-
Impact of Pre-Transplant Hypomethylating Agents on Reduced-Intensity Conditioning Allogeneic Hematopoietic Cell Transplantation in Myelodysplastic Syndrome With Good or Intermediate-Risk Cytogenetics
Alnimer, Y., Qasrawi, A., Soule, A., McAvoy, C., Hawes, N. J. & Yalniz, F. F., 2026, (Accepted/In press) In: Transplantation and Cellular Therapy.Research output: Contribution to journal › Article › peer-review
-
All-Cause and Exacerbation-Related Readmissions in Thrombotic Microangiopathy Requiring Plasmapheresis: A Population-Based Cohort Study
Thebert, A. R., Yoshino, T., Morita, S. X., Ito, M., Qasrawi, A. & Kato, H., 2025, In: Turkish Journal of Hematology. 42, 4, p. 281-289 9 p.Research output: Contribution to journal › Article › peer-review
Open Access -
Cryptic to conventional cytogenetics: Philadelphia-like ALL presenting with hypereosinophilia
Chahine, Z., Yenwong Fai, L., Wei, S. & Qasrawi, A., Jan 21 2025, In: BMJ Case Reports. 18, 1, e259811.Research output: Contribution to journal › Article › peer-review
Open Access -
Unveiling the Genetic and Clinical Differences of Acute Myeloid Leukemia (AML) in Obese Patients
Yalniz, F. F., Johnson, A., Alnimer, Y., Chahine, Z., Morris, T., Yadav, R., Taj, H., Iragavarapu, C., Munker, R., Monohan, G., Wai, S., Zhang, S., Nozad, S. & Qasrawi, A., Feb 2025, In: European Journal of Haematology. 114, 2, p. 365-372 8 p.Research output: Contribution to journal › Article › peer-review
-
Hard to find and tricky to treat: A case series of acquired amegakaryocytic thrombocytopenia
Anwar, A., Chahine, Z., Piecoro, D., Kesler, M. & Qasrawi, A., Sep 2023, In: Human Pathology Reports. 33, 300713.Research output: Contribution to journal › Article › peer-review
Open Access1 Scopus citations